Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2011 / Cilt: 45 - Sayı: 2

Pyoderma gangrenosum: retrospective evaluation of 20 cases

Piyoderma gangrenozum: 20 olgunun retrospektif değerlendirilmesi

Pages
83–87
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most of cases were as single lesions located in the lower extremities and the best treatment response was achieved by the administration of systemic corticosteroids.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: The objective of this study is to examine the clinical properties, comorbid systemic diseases and the treatment protocols of the patients diagnosed with pyoderma gangrenosum (PG).
📊
Key Findings & Data:Material and Method: Between 2003 and 2009 years, 20 patients diagnosed with pyoderma gangrenosum were evaluated in this study.
💡
Conclusion & Impact:Most of cases were as single lesions located in the lower extremities and the best treatment response was achieved by the administration of systemic corticosteroids.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Background and Design: The objective of this study is to examine the clinical properties, comorbid systemic diseases and the treatment protocols of the patients diagnosed with pyoderma gangrenosum (PG). Material and Method: Between 2003 and 2009 years, 20 patients diagnosed with pyoderma gangrenosum were evaluated in this study. The clinical properties, comorbid systemic diseases and the treatment protocols were examined retrospectively. Results: In a six-year period, 20 patients with PG (11 female and 9 male), ranging in age from 19 to 75 (mean age 45±16.39 years) were evaluated. Lesions had started as papule in 3 (16%) patients, as bullous in 1 (5%) patient, as erythematous plaque in 1 (5%) patient and as pustule in 15 (74%) patients. Whereas 14 (70%) patients had single lesion, the other patients had multiple lesions. The lesions were located at lower extremities in 14 (70%) patients most frequently, The most frequent comorbid disease in patients with pyoderma gangrenosum was inflammatory bowel diseases (colitis ulcerosa n: 4 and Crohn disease n: 2 total n: 6, 30%). The other comorbid diseases included vitiligo (n: 1, 5%), Behcet’s disease (n: 1, 5%), hidradenitis suppurativa (n: 1, 5%), deep venous thrombosis and pulmonary embolism (n: 1, 5%), pangastritis (n: 1, 5%), acute renal failure (n: 1, 5%), systemic lupus erythematosus (n: 2, 10%) and iatrogenic immunosuppression (n: 1, 5%). Systemic corticosteroid therapy was the most common treatment (n=16, 80%). The treatment response was 100% in all patients. Conclusion: In our study, inflammatory bowel diseases were the most frequent comorbid diseases with pyoderma gangrenosum. Most of cases were as single lesions located in the lower extremities and the best treatment response was achieved by the administration of systemic corticosteroids.

Özet

Amaç: Bu çalışmanın amacı piyoderma gangrenozum (PG) tanısı alan hastalardaki klinik özelliklerin, eşlik eden sistemik hastalıkların ve tedavi protokollerinin incelenmesidir. Gereç ve Yöntem: 2003-2009 yılları arasında kliniğimizde PG tanısı konulan 20 hasta çalışmaya alındı. Hastalar klinik özellikleri, eşlik eden sistemik hastalıkları ve tedavi protokolleri açısından retrospektif olarak incelendi. Bulgular: 6 yıllık izlemde, 11'i kadın ve 9'u erkek, yaşları 19-75 arasında değişen (yaş ortalaması 45±16,39), 20 PG'li hasta çalışmaya alındı. Lezyonlar 3 hastada (%16) papül, 1 (%5)'inde bül, 1 (%5)'inde eritemli plak ve 15 (%74)'inde püstül şeklinde başlamıştı. On dört (%70) hastada tek lezyon bulunurken diğer hastalarda çok sayıda lezyon bulunmaktaydı. Lezyonlar yerleşim yerine göre en sık 14 (%70) hastada alt ekstremiteydi. Piyoderma ganrenozumlu hastalarda en sık eşlik eden hastalık inflamatuvar barsak hastalığıydı (kolitis ülseroza n: 4 ve Crohn hastalığı n: 2 toplam n: 6, %30). Diğer eşlik eden hastalıklar arasında vitiligo (n: 1, %5), Behçet hastalığı (n: 1, %5), hidradenitis süpürativa (n: 1, %5), derin ven trombozu ve pulmoner emboli (n: 1, %5), pangastrit (n: 1, %5), akut böbrek yetmezliği (n: 1, %5), sistemik lupus eritematozus (n: 2, %10) ve iatrojenik immünsüpresyon (n: 1, %5) bulunmaktaydı. Sistemik kor-tikosteroidler en sık uygulanan tedaviydi (n=16, %80). Hastaların tamamında tedaviye yanıt tam olarak alındı. Sonuç: Çalışmamızda piyoderma gangrenozuma sistemik hastalıklardan en sık inflamatuvar barsak hastalıkları eşlik etmekteydi. Olguların çoğunda lezyonlar alt ekstremitede, tek lezyon şeklindeydi ve tedavide en iyi yanıt sistemik kortikosteroidlerle sağlanmıştı. (Türkderm 2011; 45: 83-7)

🔖

Cite This Article

GÜNEŞ, P., YAŞAR, Ş., AŞİRAN, Z. S. (2022). Pyoderma gangrenosum: retrospective evaluation of 20 cases. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 45 - Sayı: 2, 83–87. https://ajindex.com/articles/621970

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Mlika RB, Riahi I, Fenniche S et al: Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol 2002;41:65-8
  2. Brown TS, Marshall GS, Callen JP: Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: A rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol 2000;43:108-12
  3. Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin Dermatol 2000;18:339-47
  4. Ehling A, Karrer S, Klebl F, Schäffler A, Müller-Ladner U: Therapeutic management of pyoderma gangrenosum. Arthritis Rheum 2004;50:3076-84. 5. von den Driesch P: Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137:1000-5
  5. Blitz NM, Rudikoff D: Pyoderma gangrenosum. Mt Sinai J Med 2001;68:287-97
  6. Crowson AN, Mihm MC Jr, Magro C: Pyoderma gangrenosum: a review. J Cutan Pathol 2003;30:97-107
  7. Richetta AG, Maiani E, Carboni V et al: Pyoderma gangrenosum: case series. Clin Ter 2007;158:325-9
  8. Powell FC, Su WP, Perry HO: Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409;410-2
  9. Ahmadi S, Powell FC: Pyoderma gangrenosum: uncommon presentations. Clin Dermatol 2005;23:612-20
  10. Kim TH, Oh SY, Myung SC: Pyoderma gangrenosum of the penis. J Korean Med Sci 2009;24:1200-2
  11. Güngör E, Karakayali G, Alli N, Artüz F, Lenk N: Penile pyoderma gangrenosum. J Eur Acad Dermatol Venereol 1999;12:59-62
  12. Farrell AM, Black MM, Bracka A, Bunker CB: Pyoderma gangrenosum of the penis. Br J Dermatol 1998;138:337-40
  13. Weedon D: The vasculopathic reaction pattern: Pyoderma gangrenosum. Weedon's skin pathology. 3.th Edition, China, Churchill livingstone elsevier, 2010;196-244
  14. Reichrath J, Bens G, Bonowitz A, Tilgen W: Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-83
  15. Ah-Weng A, Langtry JA, Velangi S, Evans CD, Douglas WS: Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005;30:669-71
  16. Haim S, Friedman-Birnbaum R: Pyoderma gangrenosum in immunosuppressed patients. Dermatologica 1976;153:44-8
  17. Hasselmann DO, Bens G, Tilgen W, Reichrath J: Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007;5:560-4
  18. Waldman MA, Callen JP: Pyoderma gangrenosum Preceding the Diagnosis of Systemic Lupus erythematosus. Dermatology 20